Bear mar­ket slows Pep­Gen's roll, caus­ing DMD-fo­cused biotech to price be­low range

A month af­ter Pep­Gen tran­si­tioned to a clin­i­cal-stage com­pa­ny with its Duchenne mus­cu­lar dy­s­tro­phy tri­al in Cana­da, the Boston biotech is de­but­ing on Wall Street.

But its Nas­daq en­trance was sub­dued Fri­day with a $12 pric­ing $PEPG, falling be­low the pen­ciled-in $13 to $15 range. And Bausch Health’s eye­care prod­ucts spin­out, Bausch + Lomb, al­so faced re­al­i­ty with a launch be­low its range, at $18 $BLCO in­stead of the tar­get­ed $21 to $24 it want­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER